Abstract
SummaryIncreased uric acid levels are correlated with cardiovascular disease, particularly with ischaemic heart disease. Xanthine oxidase inhibitors, especially allopurinol, lower the risk of ischaemic heart disease due to their effects on reactive oxygen species and endothelial function. In chronic stable angina pectoris, allopurinol increases the median time to ST depression, time to chest pain, and total exercise time. On the other hand, it has been reported that allopurinol has a beneficial effect on ischaemic patients referred for angioplasty, but there are insufficient data regarding its effect on acute myocardial infarction patients. Moreover, other important actions of allopurinol are regression of left ventricular hypertrophy and improvement in the results of cardiac rehabilitation. The efficacy of allopurinol has recently been acknowledged by the European Society of Cardiology guidelines for stable angina pectoris, but the particular role of allopurinol in ischaemic heart disease patients is not fully established.
Highlights
Increased uric acid levels are correlated with cardiovascular disease, with ischaemic heart disease
In chronic stable angina pectoris, allopurinol increases the median time to ST depression, time to chest pain, and total exercise time
It has been reported that allopurinol has a beneficial effect on ischaemic patients referred for angioplasty, but there are insufficient data regarding its effect on acute myocardial infarction patients
Summary
The use of allopurinol improves chronic stable angina. Angina pectoris has a high prevalence of 5.7% in men and 6.7% in women, not all of them being referred for interventional cardiology. There are further studies which do not confirm the aforementioned results They describe no significant improvement of exercise capacity in patients with stable angina treated with allopurinol.[9,15]. The same article showed a nine-month left ventricular mass (LVM) and left ventricular mass index (LVMI) decrease of 5.2 g and 2.2 g/m2, respectively, in the allopurinol group, versus 1.3 g and 0.53 g/m2 in the placebo group, the difference being highly significant They determined the augmentation index (AIx), which was lower in the allopurinol group, suggesting improvement in endothelial function, and less vascular remodelling. Compared to the control group, allopurinol-treated patients displayed a 3.3-mmHg systolic and a 1.3-mmHg diastolic blood pressure decrease
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
